Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company’s Investigational Anti-PD-...
September 02 2014 - 8:30AM
Business Wire
First Presentation of Findings in Gastric
and Bladder (Urothelial Tract) Cancers
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today announced the presentation of data from ongoing
clinical trials evaluating the anti-tumor activity of
pembrolizumab, the company’s investigational anti-PD-1 antibody, at
the European Society of Medical Oncology (ESMO) 2014 in Madrid,
Spain, September 26 – 30. Data on pembrolizumab are planned to be
presented in five advanced solid tumor types, including the first
presentation of data evaluating pembrolizumab for the treatment of
gastric and bladder (urothelial tract) cancers. Three late-breaking
abstracts have been accepted for oral presentation.
“We are pleased to present the first data for our
investigational anti-PD-1 antibody pembrolizumab in gastric and
bladder cancers at ESMO 2014,” said Dr. Roy Baynes, senior vice
president, Global Clinical Development, Merck Research
Laboratories. “The presentation of data for five advanced tumor
types underscores the breadth of Merck’s immuno-oncology
development program evaluating pembrolizumab in diverse tumor
types, different stages of disease and multiple lines of
therapy.”
Abstracts involving Merck Oncology-sponsored studies at ESMO
2014 include:
Bladder and Gastric Cancers
- (Abstract #LBA23) Late-Breaker (Oral
presentation): A Phase 1b Study of Pembrolizumab (Pembro;
MK-3475) in Patients (Pts) With Advanced Urothelial Tract
Cancer. E. Plimack. Monday, September 29, 11:00 AM-11:15 AM
CEST. Location: Sevilla.
- (Abstract #LBA15) Late-Breaker (Oral
presentation): A Phase 1b Study of Pembrolizumab (Pembro;
MK-3475) in Patients (Pts) With Advanced Gastric Cancer. K.
Muro. Sunday, September 28. 09:15 AM-09:30 AM CEST. Location:
Madrid.
Advanced Melanoma
- (Abstract #LBA34) Late-Breaker
(Poster discussion): Pembrolizumab (Pembro; MK-3475) for
Advanced Melanoma (MEL): Randomized Comparison of Two Dosing
Schedules. C. Robert, Monday, September 29. 1:00 PM-2:00 PM
CEST. Location: Valencia.
- (Abstract #1075TiP) Poster:
KEYNOTE-029: Phase 1/2 Study of MK-3475 in Combination With
Pegylated Interferon Alfa-2b (PEG-IFN) or Ipilimumab (IPI) in
Patients (Pts) With Advanced Melanoma (MEL) or Renal Cell Carcinoma
(RCC). T.K. Choueiri. Monday, September 29; 12:45 PM-1:45 PM
CEST. Location: Poster Area.
- (Abstract #1097P) Poster:
PD-L1 Expression and Overall Survival Among Patients With
Melanoma. T. Steiniche. Sunday, September 28; 12:45 PM-1:45 PM
CEST. Location: Poster Area.
NSCLC
- (Abstract #LBA43) Late-Breaker (Oral
presentation): Antitumor Activity of Pembrolizumab (Pembro;
MK-3475) and Correlation With Programmed Death Ligand 1 (PD-L1)
Expression in a Pooled Analysis of Patients (pts) With Advanced
Non–Small Cell Lung Carcinoma (NSCLC). E. Garon. Sunday,
September 28; 09:15 AM-10:30 AM CEST. Location: Barcelona.
- (Abstract #1328P) Poster:
PD-L1 Expression and Survival Among Advanced Non–Small Cell Lung
Cancer (NSCLC) Patients Treated With Chemotherapy. S. Sorensen.
Saturday, September 27; 12:45 PM-1:45 PM CEST. Location: Poster
Area.
Head and Neck Cancer
- (Abstract #LBA31) Late-Breaker
(Poster discussion): A Phase Ib Study of Pembrolizumab
(Pembro; MK-3475) in Patients (Pts) With Human Papillomavirus Virus
(HPV)-Positive and Negative Head and Neck Cancer (HNC). L.
Chow. Sunday, September 28; 1:00 PM-2:00 PM CEST. Location: Poster
Area.
For more information about the ESMO Congress and for a complete
list of abstract titles, please refer to
www.esmo.org/Conferences/ESMO-2014-Congress.
About Pembrolizumab
Pembrolizumab (MK-3475) is a humanized monoclonal antibody that
blocks the interaction between PD-1 and its ligands, PD-L1 and
PD-L2. By binding to the PD-1 receptor and blocking the interaction
with the receptor ligands, pembrolizumab releases the PD-1
pathway-mediated inhibition of the immune response, including the
anti-tumor immune response.
Pembrolizumab is currently being evaluated across more than 30
types of cancers, as monotherapy and in combination. It is
anticipated that by the end of 2014, the pembrolizumab development
program will grow to more than 24 clinical trials, enrolling an
estimated 6,000 patients at nearly 300 clinical trial sites
worldwide. For information about Merck’s oncology clinical trials,
please visit http://www.merck.com/clinical-trials/index.html.
Our Focus on Cancer
Our goal is to translate breakthrough science into biomedical
innovations to help people with cancer worldwide. For Merck
Oncology, helping people fight cancer is our passion, supporting
accessibility to our cancer medicines is our commitment, and
pursuing research in immuno-oncology is our focus to potentially
bring new hope to people with cancer. For information about Merck’s
commitment to Oncology visit the Oncology Information Center at
http://www.mercknewsroom.com/oncology-infocenter.
About Merck
Today's Merck is a global healthcare leader working to help the
world be well. Merck is known as MSD outside the United States and
Canada. Through our prescription medicines, vaccines, biologic
therapies, and consumer care and animal health products, we work
with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit
www.merck.com and connect with us on Twitter, Facebook and
YouTube.
Forward-Looking Statement
This news release includes “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. These statements
are based upon the current beliefs and expectations of Merck’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include, but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and healthcare
legislation in the United States and internationally; global trends
toward healthcare cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of Merck’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
Merck undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in Merck’s 2013 Annual
Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
MerckMedia Contacts:Ian McConnell, 908-423-3046Claire Mulhearn,
908-423-7425Investor Contacts:Joseph Romanelli, 908-423-5185Justin
Holko 908-423-5088
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024